Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).
Expert Panel of GESIDA and the National AIDS Plan; Berenguer J, Polo R, Aldeguer JL, Lozano F, Aguirrebengoa K, Arribas JR, Blanco JR, Boix V, Casado JL, Clotet B, Crespo M, Domingo P, Estrada V, García F, Gatell JM, González-García J, Gutiérrez F, Iribarren JA, Knobel H, Llibre JM, Locutura J, López JC, Miró JM, Moreno S, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz-Moreno J, Sanz J, Téllez MJ, Tuset M, Rivero A. Expert Panel of GESIDA and the National AIDS Plan, et al. Among authors: estrada v. Enferm Infecc Microbiol Clin. 2015 Oct;33(8):544-56. doi: 10.1016/j.eimc.2015.03.017. Epub 2015 May 26. Enferm Infecc Microbiol Clin. 2015. PMID: 26021186
Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Barrios A, Negredo E, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Santos J, Clotet B, Soriano V; EFADITE Study Group. Barrios A, et al. Among authors: estrada v. Antivir Ther. 2005;10(7):825-32. Antivir Ther. 2005. PMID: 16312178 Clinical Trial.
[Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection].
Polo R, José Galindo M, Martínez E, Alvarez J, Arévalo JM, Asensi V, Cánoves D, Cáncer E, Collazos J, Estrada V, Gómez-Candela C, Johnston S, Locutura J, López-Aldeguer J, Lozano F, Miralles C, Muñoz-Sanz A, Ortega E, Pascua J, Pedrol E, Pulido F, San Martín M, Sanz J, Viciana P, Chamorro L; Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS). Polo R, et al. Among authors: estrada v. Enferm Infecc Microbiol Clin. 2006 Feb;24(2):96-117. doi: 10.1157/13085017. Enferm Infecc Microbiol Clin. 2006. PMID: 16545318 Spanish.
Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study.
Moreno S, Domingo P, Palacios R, Santos J, Falcó V, Murillas J, Estrada V, Ena J, Alvarez ML; Recover Study Group. Moreno S, et al. Among authors: estrada v. J Acquir Immune Defic Syndr. 2006 Jul;42(3):385-7. doi: 10.1097/01.qai.0000221690.54349.83. J Acquir Immune Defic Syndr. 2006. PMID: 16763528 No abstract available.
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
Youle M, Staszweski S, Clotet B, Arribas JR, Blaxhult A, Carosi G, Dejesus E, Di Perri G, Estrada V, Fisher M, Kovacs C, Kulasegaram R, Lazzarin A, Marriott D, Muñoz L, Reynes J, Shalit P, Slim J, Tsoukas C, Vaccaro A, Vera J. Youle M, et al. Among authors: estrada v. HIV Clin Trials. 2006 Mar-Apr;7(2):86-96. doi: 10.1310/2xvk-pbgl-735n-wh72. HIV Clin Trials. 2006. PMID: 16798623
[Darunavir in treatment-naïve patients. The ARTEMIS study].
Estrada V, Fuster M. Estrada V, et al. Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:10-3. doi: 10.1016/s0213-005x(08)76548-0. Enferm Infecc Microbiol Clin. 2008. PMID: 19195454 Clinical Trial. Spanish.
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
Pulido F, Pérez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, Rubio R, González-García J, Miralles P, Pérez-Elías MJ, Ocampo A, Hernando A, Estrada V, Clotet B, Podzamczer D, Arribas JR. Pulido F, et al. Among authors: estrada v. Antivir Ther. 2009;14(2):195-201. doi: 10.1177/135965350901400210. Antivir Ther. 2009. PMID: 19430094
286 results